Breaking News on Drug Discovery
All news articles > February 2006
| « Previous month | Next month » |
28-Feb-2006
Drug collaboration focuses on infectious disease targets
Graffinity, announced today that it has entered into its second research collaboration with Mutabilis, which aims to discover novel therapeutics for infectious diseases, building on 2003's collaboration focusing on another anti-infective drug target.
Isis and Rosettta form microRNA therapy deal
Isis Pharmaceuticals and Rosetta Genomics has announced a joint research collaboration to develop microRNA related therapies for the treatment of liver cancer, demonstrating the therapeutic potential of microRNA as a drug target using antisense.
Abbott selects two more cancer targets from Celera deal
Celera Genomics has announced that Abbott has selected two additional cancer targets for further development, which brings the total of targets to four under investigation as a result of the collaboration between the companies to discover and commercialise therapies for cancer treatment.
Rigel completes arthritis drug interaction study
Rigel has completed the Phase I stage of its drug interaction study in patients with rheumatoid arthritis. The oral syk kinase inhibitor could be an improvement over current treatment options, which have side effects that include gastrointestinal complications and kidney damage.
New drug proves effective against resistant and latent TB
An experimental TB drug has proved effective against multi drug-resistant forms of the disease as well as becoming the first compound to treat the latent stage of this disease, which affects nearly a third of the world's population, of which approximately 2 billion people are latently infected.
23-Feb-2006
Thermo introduces LIMS datasheet for pharma industry
Thermo Electron makes available a new datasheet to provide an overview of the capabilities of its Watson Laboratory Information Management System (LIMS), which is designed to support drug metabolism and pharmacokinetic (DMPK) studies in drug discovery and development.
New research gives scientists powerful drug discovery tool
A consortium of US scientists have developed and evaluated a robust new system for analysing how drugs bind to proteins, which could speed up the delivery of potential new drugs and improve existing ones.
eClinical trials uptake meets industry resistance
According to a new report, the adoption of eClinical technologies has been hampered by the ability to take the electronic revolution to the next level, as the adoption of eClinical technologies currently remain confined to localised start-up projects.
Biofusion launches spin-out company Genophrenix
Biofusion has announced the creation of Genophrenix, a new spin-out company that aims to focus on treatments originating from biochemical pathways implicated in a range of neuropsychiatric diseases, including schizophrenia.
Protein molecule isolated as neurodegenerative drug target
Researchers have isolated a protein molecule that may hold the key to learning and memory disorders that have been linked with autism. By isolating this potential drug target, new therapies for diseases in which synapses either fail or proliferate out of control could be produced.
21-Feb-2006
Ceragenix' drug compound found to kill HIV strains
A consortium of researchers has detailed the activity of a novel drug compound that kills multiple HIV strains via a unique mechanism of action. The discovery brings with it hope in using this compound in both topical and systemic applications for HIV therapy.
Novartis and Alnylam enter pandemic flu collaboration
Swiss pharma giants, Novartis has formed a collaboration with Alnylam, which aims to develop an RNAi-based therapeutic for pandemic flu. The deal is in response to analysts who believe that current vaccines and existing anti-viral agents may not be sufficient to protect against newly emerging strains of influenza virus.
Ark breakthrough may increase cancer therapies efficacy
A unique DNA-based targeting technology has shown to halt tumour progression with significantly smaller chemotherapy doses opening the way to reduce the side effects as well as increase the efficacy of anti cancer therapies.
Wine compound extract used as anti-aging drug?
A natural compound could become the starting molecule for the design of drugs that prolongs lifespan and delay the onset of aging-related traits in vertebrate organisms, supporting the potential utility of the compound in human aging research.
Asynt launches affordable parallel reactor
Asynt have launched the first affordable 500ml parallel reactor on the market with its latest addition to the DrySyn range, providing a safe and flexible alternative to oil bath and mantles.
16-Feb-2006
Scientists stumble on potential arthritis drug target
Scientists exploring inflammation in rheumatoid arthritis have made an unexpected discovery that may lead to new drug treatments to ease the pain and discomfort endured by 66 million (nearly 1 in 3 adults) US citizens in 2005.
SIPLAS sign agreement for clinical trial support
Contract Research Organisation (CRO) Averion, and the SIPLAS Research Organisation has signed an agreement to provide promotion and support of clinical trials in a move that that reinforces Latin America as an emerging hub of clinical trial service providers.
New ReactArray Solo aids drug patent protection
A collaboration between Anachem and chemists within the pharmaceutical industry has resulted in the launch of the new ReactArray Solo, which is designed to provide faster, more efficient polymorph screening to aid drug patent protection by enabling runs of upto 48 different reaction conditions simultaneously.
Singapore MTI announces S$7.5bn investment
Singapore's commitment to pharmaceutical research and development goes from strength to strength after its government granted S$7.5bn (€3.9bn) to sustain the innovation-driven growth the country has experienced as Asia's main drug research hub.
Honeywell launches improved BMI activator
Honeywell launches a new formulation of BMI activator, which is used to synthesise DNA and RNA oligonucleotides for therapeutic and medical diagnostic applications. The formulation aims to result in higher yields and lower overall operational costs compared to traditional Tetrazole activator solutions.
14-Feb-2006
Phoqus completes Phase I Chronocort clinical study
Oral drug development company, Phoqus, has announced that it has completed Phase I of its clinical study on Chronocort, the first circadian endocrine treatment for adrenal insufficiency that current steroid therapies for this condition do not mimic.
Waters introduces new capabilities for proteomic research
Waters Corporation has introduced new capabilities for proteomic research by enhancing its bioanalysis software, which will allow researchers to identify and quantify proteins and biomarkers more efficiently.
Amgen expands existing Biovitrum diabetes deal
Biotechnology company, Amgen, and Biovitrum have expanded its existing license agreement for its treatment of metabolic disorders, focusing on type 2 diabetes, which currently afflicts over 160 million people worldwide.
Genospectra deal strengthens Sigma assay position
Sigma-Aldrich has strengthened its position in the RNAi and cell-based assay market by signing a series of agreements in which the life science company has acquired a minority equity stake in Genospectra and is granted access to various Genospectra technologies.
Arpida presents positive trial oral iclaprim data
Arpida has announced it has successfully completed a Phase I clinical trial with oral iclaprim in a capsule formulation. This broad-spectrum antibiotic targets infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
09-Feb-2006
Supelco introduces HPLC column
Supelco, a division of Sigma-Aldrich, introduces its HPLC Column, which offers improved retention power and resolution for difficult-to-separate analytes. The column becomes the latest in the Ascentis' family range, adding to the flexibility needed for sensitive MS applications.
Glaxo 4Q earnings set up acquisitive speculation
GlaxoSmithKline (GSK) publishes its fourth quarter earnings, which indicate a significant profit rise well ahead of industry predictions, with momentum building in its product pipeline of new drugs giving the company the go-ahead to look into potential acquisitions.
New service improves pharma research applications
The industry trend in outsourcing opportunities shows no sign of weakening as contract researchers, easyRegDocs, introduced a new service that aims to simplify the process of completing clinical trial documentation, saving time and money.
Scientists re-engineer antibiotic to counter drug resistance
Scientists have re-engineered a well-known antibiotic to counter drug resistance forming a new molecule in the process that could assist in treating hospital infections, which were previously resistant to common antibiotics putting its use under the spotlight.
Novascreen launches next gen drug screening service
NovaScreen BioSciences introduces a new side effect panel, which aims to improve procedures in identifying potential risk factors of drug candidates, by incorporating a broader range of receptor subtype assays, which target a broader range of therapeutic areas.
07-Feb-2006
New lab systems optimises liquid handlers
ARTEL announces a new laboratory innovation to improve the performance of automated liquid handlers, introducing a system capable of verifying multichannel instrumentation using non-aqueous test solutions, such as Dimethyl Sulfoxide (DMSO).
New drug-academia deal trains future 'pharma stars.'
A UK university has joined forces with a major pharmaceutical company in a unique collaboration, worth £2.5 million (€3.6 million) ensuring drug researchers of the future will be trained in 'magic bullet' drug R&D, which has been hailed as the next generation of pharmaceutical therapy.
Molecular Devices launches IMAP detection system
Molecular Devices has launched its proprietary system, which offers Fluorescence Polarisation (FP) and Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) detection, allowing researchers to select between these two well-known detection methods without changing technologies.
Evotec completes Phase I component for Alzheimer's drug
Evotec has announced the successful completion of the single ascending dose component of its phase I trial for its subtype-specific NMDA receptor antagonist drug candidate for the treatment of Alzheimer's disease.
Affymetrix and Iconix deal assesses drug toxicity
Affymetrix and Iconix have formed a collaboration to develop new solutions for assessing the toxicological and pharmacological properties of drugs and drug candidates.
02-Feb-2006
GE Healthcare announces high performance fast flow products
GE Healthcare has launched a new line of uncharged IMAC media suitable for both research and process scale-up applications, which combines high flow rate and high binding capacity, which give researchers the power to select the metal ion that maximises selectivity for their specific target protein.
Automation and integration fuels laboratory growth
According to a new report, automation technologies and integrated systems are set to fuel growth in the clinical laboratory analyser markets, accelerating the movement towards increased workstation consolidation and more streamlined procedures.
SurModics deal results in novel synthetic ECM
Surmodics has announced that as a result of a collaboration with the Donaldson Company, the first of a collection of new synthetic nanofibrillar cell culture surfaces have been produced that will improve cell culture, cell-based bioassays and other in vitro (laboratory-based) cell-related applications used in drug discovery.
Amgen's new facilities boosts UK drug R&D
Amgen are to create a European Development Centre significantly boosting UK drug R&D. The announcement echoes the UK Government's commitment to attract more R&D investment with a view to making the UK a leader in biotechnology.
New law halves UK animal extremist attacks
Animal extremist activity in the UK may be on the wane after 2005 saw incidents of damage to company, personal and public property, halve compared to 2004. The figures indicate the effectiveness of the Serious Organised Crime Act, as a deterrent, which came into effect halfway through last year.
| « Previous month | Next month » |
All Decision News Media Sites
Food & Beverage: Food & Beverage Development - Europe | Food & Beverage Development - North America | Food Marketing and Retailing | Food Processing & Packaging | Food Safety & Quality Control | Food and Beverage in Asia Pacific | Industrial Baking & Snacks | Beverage Technology & Markets | Confectionery & Biscuit Processing | Dairy Processing & Markets | Prepared Food and Meat Processing | Retail news Nutrition: Supplements & Nutrition - Europe | Supplements & Nutrition - North America Pharmaceutical: Pharmaceutical Technology | Contract Research, Manufacturing & Clinical Trials Cosmetics: Cosmetics Formulation & Packaging - North America | Cosmetics Formulation & Packaging - Europe
About us | Site map | All sites | Recommend this Site | Advertise | Contact the Editor | Terms & Conditions | Privacy Policy
©; 2000/2010 - Decision News Media SAS - All right reserved.
